Navigation Links
Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
Date:5/7/2012

acted as the exclusive advisor to Coherus BioSciences in this licensing partnership with Daiichi Sankyo.

About Coherus BioSciences

Coherus BioSciences is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area with an entirely new model for developing safe, high-quality biosimilar therapeutics.  Founded in 2010, Coherus already has formed global partnerships with top tier pharma and filled the pipeline with five product candidates focused on treating oncology and inflammatory diseases.  Led by a group of early biotech pioneers, Coherus has reinvented the entire business of developing biologic medicines, from concept to commercialization, so that more patients around the world can have greater access to quality therapeutics. For additional information, please visit www.coherus.com.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

Contact: Maureen Lopez
Coherus BioSciences
Phone Number 1-800-794-5434

Media contact for Daiichi Sankyo Co. Ltd.: +81-3-6225-1126


'/>"/>
SOURCE Coherus BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
2. Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
3. DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study
4. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
5. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
6. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
8. Milestone Biosciences, LLC Further Strengthens Executive Management Team
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
11. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Deep Research Report on ... in-depth research report on the Ammonium Bifluoride market, ... classification, application, and industry chain structure as well ... market analysis, including China’s domestic market as well ... China, Japan etc. regions) industry analysis covering macroeconomic ...
(Date:11/26/2014)... PHILADELPHIA , Nov. 26, 2014 ... environments. Human exploration of space requires astronauts to maintain ... safety and success, and prevent potential errors and accidents. ... little is known about how cognition is affected by ... affected. Now, Penn Medicine researchers are poised ...
(Date:11/26/2014)... PMG Research, Inc. announced today ... a network of sites that provide clinical research services to ... patient lives through its partnerships with large physician practices and ... site locations in the Southeastern United States and spans over ... board will be held by: Dr. Robert Holmes, ...
(Date:11/26/2014)... TX (PRWEB) November 25, 2014 Continuing ... skincare products, earned three prestigious MarCom Awards for outstanding ... Nerium received a Platinum MarCom Award, the organization’s top ... Event in St. Louis held in April of this ... more than 14,000 attendees. Additionally, Nerium was awarded a ...
Breaking Biology Technology:Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2
... Aug. 22 DNA2.0,Inc. (http://www.DNA20.com ), ... and,Operon Biotechnologies (http://www.operon.com ), a leader ... a partnership to utilize their,synergistic technologies and ... production platform with DNA2.0,s,gene synthesis process, the ...
... 21 ,Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... (SAR) of a class of,internally-developed compounds that ... the company as potential treatments for irritable ... is currently,under evaluation in a Phase 1b ...
... Under Fire, WORCESTER, Mass., Aug. 21 ... proud to announced that Dr.,Robert Lanza, the company,s ... recognized for his research and contributions to stem,cell ... PharmaVOICE (cover,story July/August issue). Dr. Lanza is one ...
Cached Biology Technology:Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 3Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 2Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 3
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... alarming invasion of round goby into Great Lakes tributaries: ... A team of scientists from the University of Toronto, ... of Guelph has identified a drastic invasion of round ... of the Thames, Sydenham, Ausable and Grand Rivers. A ...
... awarded through federal stimulus research funding, a Kansas State ... eventually help diabetics preserve their eyesight. Dolores Takemoto, ... from the National Eye Institute to study how a ... protein kinase C gamma, called PKC gamma, and how ...
... , , , WALL, N.J., Aug. ... will be holding its second quarter conference call, which will be broadcast ... Eastern Time. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , ... International, Inc. Second Quarter 2009 Conference Call, When: ...
Cached Biology News:BIO-key(R) Announces Second Quarter Conference Call Schedule 2
Human GATA-2 Affinity Purified Polyclonal Ab...
... microPET 120 utilizies CTI Molecular Imaging's proprietary ... same imaging volume as the R4. ... sensitivity of any commerically avaiable PET scanner. ... spatial resolution of any scinitallor based PETsystems. ...
... EVO series offers versatile liquid handling platforms ... a wide variety of life science applications.The ... base sizes (75, 100, 150 and 200 ... a platform that will advance with their ...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
Biology Products: